Hanmi Science, the holding company of Hanmi Group, recorded sales of 1 trillion won by the third quarter following its transition to a professional management system.
On October 29, Hanmi Science announced its provisional consolidated results for the third quarter of this year, reporting sales of 342.5 billion won, operating profit of 39.3 billion won, and net profit of 31.9 billion won. Compared to the same period last year, sales increased by 6.2%, while operating profit and net profit rose by 75.2% and 84.8%, respectively.
Cumulative sales for the first three quarters reached 1.0129 trillion won, up 6.4% year-on-year. Operating profit stood at 101 billion won and net profit at 84.7 billion won, solidifying a stable foundation for the company.
A Hanmi Science representative stated, "The strong third-quarter results were driven by increased sales in both the pharmaceutical distribution and healthcare business divisions," adding, "Based on the professional management system, we are strengthening the organic collaboration structure among group companies and establishing a 'business-oriented holding company' model centered on R&D and new businesses, which is already delivering concrete results in a short period of time."
After adopting a professional management system in March, Hanmi Science has been working to enhance group synergy and management efficiency, while accelerating its growth strategy through open innovation.
The Innovation Division, overseen by Vice Chairman Kim Jaekyo, consists of the C&D (Connect & Development) Strategy Team responsible for discovering partnerships, the L&D (Launching & Development) Strategy Team leading the commercialization of internal pipelines, and the IP Team in charge of patent management and support. Through close collaboration with the R&D Center, the company is implementing a dual growth strategy that combines internal development with external technology.
Amid this innovation drive, Hanmi Science's healthcare business division posted third-quarter sales of 39.1 billion won, up 26.9% year-on-year, while the pharmaceutical distribution division (Onlinepharm) achieved 287.1 billion won in sales, driven by domestic market expansion. JVM, a company specializing in pharmaceutical automation systems, continues its robust growth by expanding its portfolio with the launch of the new COUNTMATE product for the North American market.
Core subsidiary Hanmi Pharmaceutical is strengthening its global competitiveness through the early announcement of interim topline results from the Phase 3 trial of "Efeglenatide," which is gaining attention as Korea's first obesity drug, as well as a recent technology transfer agreement for "Ensacuita" with global pharmaceutical company Gilead Sciences.
In addition, externally prescribed sales of proprietary drugs such as the combination therapy for dyslipidemia "Rosuzet," the hypertension product group "Amozaltan Family," and the gastroesophageal reflux disease product group "Esomezol Family" have shown steady growth. The low-dose triple antihypertensive "Amoprel," launched in August, is attracting market attention as a new option for initial hypertension treatment.
Kim Jaekyo, CEO of Hanmi Science, stated, "Hanmi Science is faithfully fulfilling its role as a holding company, while also creating new growth opportunities based on open innovation as a competitive business-oriented holding company that generates revenue through direct business activities. Going forward, we will continue to anticipate the future growth engines of our group affiliates and lead Hanmi Group's sustainable growth by expanding our business domains."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
